Transplantation & Cellular Therapy

The latest news, research, and perspectives in transplantation and cellular therapy. Autologous and allogeneic hematopoietic stem cell transplantation represent potentially curative options for some patients, while the field of non-transplant cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, CAR natural killer cell therapies, and genetically modified T-cell receptors, is also expanding to offer more patients curative options.

Melissa BadamoAggressive B-Cell Lymphoma | June 3, 2024
Patients with relapsed refractory LBCL can derive clinical benefit from liso-cel NCP without compromising safety.
Read More
Melissa BadamoFollicular Lymphoma | June 3, 2024
The median progression-free survival, duration of response, and overall survival were not reached.
Leah LawrenceTransplantation & Cellular Therapy | May 22, 2024
Benefits of CAR T-cell therapy outweigh the hypothetical future risk of secondary malignancies.
Magdi Elsallab, MD, PhDTransplantation & Cellular Therapy | April 17, 2024
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
Melissa BadamoTransplantation & Cellular Therapy | May 21, 2024
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
Sarah ValentineAcute Myeloid Leukemia | April 2, 2024
HMA plus venetoclax was found to be effective and well tolerated in patients with AML who relapsed after HSCT.
Sarah ValentineAggressive B-Cell Lymphoma | March 26, 2024
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
Douglas Tremblay, MDMyelodysplastic Syndromes | March 15, 2024
The study also explored the role of this combination in transitioning patients to HSCT.
Melissa BadamoAcute Myeloid Leukemia | March 7, 2024
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
Cecilia BrownIndolent B-Cell Lymphoma | March 8, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Richard Newcomb, MDTransplantation & Cellular Therapy | February 26, 2024
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
Melissa BadamoMyeloma | March 19, 2024
The study used public data from various online sources related to approved CAR-T therapies for MM.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Melissa BadamoPrint | February 8, 2024
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Patrick DalyPrint | February 7, 2024
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Chadi Nabhan, MD, MBA, FACPTransplantation & Cellular Therapy | January 26, 2024
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Patrick DalyTransplantation & Cellular Therapy | February 2, 2024
Patients' coping strategies prior to HSCT had significant effects on their psychological distress and quality of life.
Blood Cancer TalksBlood Cancer Talks | January 24, 2024
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
Leah SherwoodTransplantation & Cellular Therapy | January 5, 2024
GVHD affects approximately 30,000 Americans, according to Dr. Michael Chancellor, Chief Medical Officer at Lipella.
Ajai Chari, MDTransplantation & Cellular Therapy | January 24, 2024
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Afaf Osman, MDAcute Myeloid Leukemia | March 5, 2024
Dr. Osman discussed menin inhibitors for leukemia, and axatilimab treatment for graft-versus-host disease.
Patrick DalyMyelofibrosis | October 12, 2023
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.
Leah LawrenceTransplantation & Cellular Therapy | February 8, 2024
Here’s what they add to the treatment toolbox for hematologic malignancies.
The Fellow on CallThe Fellow on Call | October 10, 2023
In this episode of "The Fellow on Call," the hosts focus on CAR-T, bispecific antibodies, and more.
Chadi Nabhan, MD, MBA, FACPTransplantation & Cellular Therapy | February 8, 2024
Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products.
Cecilia BrownChronic Lymphocytic Leukemia | September 1, 2023
Ibrutinib has a monthly sticker price of $17,000 and was taken by 20,000 people who were beneficiaries of Medicare.
Cecilia BrownTransplantation & Cellular Therapy | August 29, 2023
Critical drugs used to treat cancer are in short supply in the United States and around the globe.
Cecilia BrownMantle Cell Lymphoma | September 19, 2023
Researchers conducted the study because patients with TP53-mutated disease “have poor outcomes with standard approaches."
Cecilia BrownMyeloma | August 21, 2023
CART-ddBCMA is an investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma.
Cecilia BrownMyeloma | August 16, 2023
There was a median of two production slots per month from March 2021 to October 2021. All slots were filled.
Leah SherwoodAcute Myeloid Leukemia | July 28, 2023
The difference in infection rates between the treatment and placebo groups was not statistically significant.
Cecilia BrownPrint | August 21, 2023
Dr. DiPersio discusses events that shaped his career, his lab’s most transformative research, and the future of transplant.
Cecilia BrownTransplantation & Cellular Therapy | April 17, 2023
Omidubicel-onlv is a “substantially modified” allogeneic cord blood-based cell therapy.
Cecilia BrownTransplantation & Cellular Therapy | April 13, 2023
Dr. June has made “seminal contributions” to CAR T-cell therapy for blood cancers,
Cecilia BrownTransplantation & Cellular Therapy | April 10, 2023
Nearly half of caregivers reported a high use of approach-oriented coping strategies.
Cecilia BrownTransplantation & Cellular Therapy | March 3, 2023
None of the patients with DDX41 variants who received post-HSCT cyclophosphamide developed severe acute GVHD.
Cecilia BrownTransplantation & Cellular Therapy | March 2, 2023
The overall neutrophil response rate, defined as recovery or improvement, was 84% within a median of nine days.
Cecilia BrownViewpoints | March 9, 2023
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | August 1, 2023
Dr. Bishop discusses the matter with host Chadi Nabhan, MD, MBA, FACP, and speaks about why CAR-T doesn't always work.
Cecilia BrownMeeting News | February 21, 2023
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Cecilia BrownTransplantation & Cellular Therapy | February 21, 2023
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Leah SherwoodTransplantation & Cellular Therapy | February 17, 2023
The study used natural language processing for computer-assisted review of electronic health records.
Cecilia BrownMyeloma | February 16, 2023
The investigators plan to continue using the monitoring strategies and further study patient outcomes.
Cecilia BrownVideo Insights | March 13, 2023
The research has implications for patients with hematologic malignancies who need to undergo allogeneic HSCT.
Cecilia BrownMyeloma | March 8, 2023
BMS-986393, a GPRC5D-directed CAR-T, had a "favorable” safety profile with “promising” preliminary efficacy in R/R MM.
Cecilia BrownPrint | January 13, 2023
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Cecilia BrownTransplantation & Cellular Therapy | February 8, 2024
Post-transplant cyclophosphamide]-based GVHD prophylaxis mitigates the development of gastrointestinal GVHD.
Leah SherwoodAcute Lymphoblastic Leukemia | May 11, 2023
Children with R/R B-cell ALL who received co-administered CD19-and CD22-directed CAR-T therapy had a 99% CR.
Latest Posts

June 21, 2024